Itraconazole + Vfend - voriconazole
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Antifungal Prophylaxis of Invasive Fungal Infections
Conditions
Antifungal Prophylaxis of Invasive Fungal Infections
Trial Timeline
Mar 1, 2006 → Feb 1, 2009
NCT ID
NCT00289991About Itraconazole + Vfend - voriconazole
Itraconazole + Vfend - voriconazole is a phase 3 stage product being developed by Pfizer for Antifungal Prophylaxis of Invasive Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00289991. Target conditions include Antifungal Prophylaxis of Invasive Fungal Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00289991 | Phase 3 | Completed |
Competing Products
1 competing product in Antifungal Prophylaxis of Invasive Fungal Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Pre-clinical | 23 |